Erubin 2 mg/ml (IV Infusion)

Indications

• Adjuvant therapy for breast cancer with axillary node tumor involvement

Pharmacology

• Cytotoxic properties
• Inhibits DNA and RNA synthesis
• Metabolism by liver and other organs
• Excretion through biliary and urinary routes

Dosage & Administration

• Intravenous infusion administration
• Repeated 3-to 4-week cycles
• Recommended dose of 100 to 120 mg/m²
• Different regimens like CEF-120 and FEC-100

Interaction

• Close monitoring with cardioactive compounds
• Interactions with Cimetidine, Paclitaxel, Docetaxel, and radiation therapy
• Impact of hepatic function changes

Contraindications

• Known hypersensitivity to Epirubicin or other anthracyclines

Side Effects

• Myelosuppression
• Cardiotoxicity
• Alopecia
• Nausea
• Vomiting
• Diarrhea
• Rash
• Anorexia

Pregnancy & Lactation

• Pregnancy Category D
• Potential risk to the fetus
• Unknown excretion in human milk

Precautions & Warnings

• Storage at refrigerated conditions
• Baseline assessment of blood counts, hepatic function, and cardiac function
• Monitoring for myelosuppression and cardiotoxicity

Use in Special Populations

• Dosage adjustments for hematologic and non-hematologic toxicities
• Consideration for bone marrow dysfunction
• Lack of specific recommendations for hepatic impairment
• Consideration for renal impairment
• No established safety and effectiveness in pediatric patients
• Particular care in monitoring toxicity in elderly female patients

Overdose Effects

• Supportive treatment in case of overdose
• Observation for signs of congestive heart failure over time

Therapeutic Class

• Cytotoxic Chemotherapy

Storage Conditions

• Refrigeration at 2-8°C
• Protection from light

Related Brands

• Farmorubicin 2 mg/ml (IV Infusion) - pfizer